Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
PARSIPPANY, N.J., April 20, 2012 /PRNewswire/ –Watson Pharmaceuticals, Inc.
Read More..Posted on April 20, 2012 | Filed under Urology News | Permalink
Archive for Urology News
Chemo + Radiation Best for Bladder Cancer, Study Finds
WEDNESDAY, April 18 (HealthDay News) — The addition of two well-tolerated chemotherapy drugs to radiation therapy led to significantly longer survival rates among patients with muscle-invasive bladder cancer.
Read More..Posted on April 20, 2012 | Filed under Urology News | Permalink
Watson Confirms Glumetza® Patent Challenge
PARSIPPANY, N.J., April 19, 2012 /PRNewswire/ –Watson Pharmaceuticals, Inc. (NYSE: WPI – News) today confirmed that its subsidiary, Watson Laboratories, Inc
Read More..Posted on April 20, 2012 | Filed under Urology News | Permalink
Watson Launches Generic FORTAMET(R)
PARSIPPANY, N.J., April 19, 2012 /PRNewswire/ –Watson Pharmaceuticals, Inc.
Read More..Posted on April 20, 2012 | Filed under Urology News | Permalink
Warren Buffett Has Early Stage Prostate Cancer
WEDNESDAY, April 18 (HealthDay News) — U.S. billionaire investor Warren Buffett says he has prostate cancer and will undergo radiation treatment in the coming months.
Read More..Posted on April 20, 2012 | Filed under Urology News | Permalink
Adding Chemo to Radiation Cuts Bladder Cancer Recurrence (CME/CE)
(MedPage Today) — Giving combination chemotherapy at the same time as radiation can reduce recurrence in bladder cancer patients, researchers found.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 18, 2012 | Filed under Urology News | Permalink
Experts Upbeat on Buffett Cancer Prognosis
(MedPage Today) — American investor Warren Buffett likely can bank on a cure for his early-stage prostate cancer, experts say.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 18, 2012 | Filed under Urology News | Permalink
IMRT Best Option for Prostate Cancer (CME/CE, with video)
(MedPage Today) — For prostate cancer patients, intensity-modulated radiation therapy (IMRT) may offer better disease control with fewer adverse effects than standard radiation therapy, but proton therapy won’t provide additional benefits, researchers found.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 18, 2012 | Filed under Urology News | Permalink
Drugs of Limited Benefit Against Urine Leakage (CME/CE)
(MedPage Today) — There are few data to show that drugs for urge urinary incontinence improve quality of life or have differences in comparative efficacy, a government-commissioned study found.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 13, 2012 | Filed under Urology News | Permalink
FDA Orders New Labeling on Finasteride
WASHINGTON (MedPage Today) — Labeling for finasteride (Propecia/Proscar) will soon have an expanded list of potential sexual adverse events, the FDA announced.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 13, 2012 | Filed under Urology News | Permalink
Gene Variants Linked to Prostate Ca Risk (CME/CE)
(MedPage Today) — Two germ-line variants have emerged as significant risk factors for prostate cancer development and progression, data from a large cohort study showed.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 10, 2012 | Filed under Urology News | Permalink
Antifungal May Help in Prostate Cancer (CME/CE)
CHICAGO (MedPage Today) — Men with castration-resistant prostate cancer experienced better outcomes when treated with the antifungal itraconazole.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 6, 2012 | Filed under Urology News | Permalink
PodMed: A Medical News Roundup from Johns Hopkins (with audio)
(MedPage Today) — This week’s topics include video to promote organ donations, mammography ‘plus’ for breast cancer diagnosis, and a possible link between a common antibiotic and detached retinas.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 6, 2012 | Filed under Urology News | Permalink
‘Choose Wisely’ Project Lists Overused Tests
(MedPage Today) — Nine specialty groups have listed tests and treatments that are frequently overused, such as antibiotics for sinus attacks and CT scans for low back pain, in the first phase of a long-term project.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 5, 2012 | Filed under Urology News | Permalink
Cancer Diagnosis May Prompt Suicide, MI (CME/CE)
(MedPage Today) — Receiving a cancer diagnosis can take an immediate and major toll on a patient, both mentally and physically, a Swedish study suggested.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 5, 2012 | Filed under Urology News | Permalink
Overactive Bladder Drug Risks Highlighted
?WASHINGTON (MedPage Today) — Mirabegron, an investigational drug for overactive bladder, is effective at reducing symptoms of urinary incontinence but has worrisome cardiovascular side effects and may be harmful to the liver, according to FDA staff reviewers.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 3, 2012 | Filed under Urology News | Permalink
Urine Odor Signals UTI in Infants (CME/CE)
(MedPage Today) — ?Bad-smelling urine is a good predictor of urinary tract infection (UTI) in infants — better than several other associated predictors, researchers found.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 2, 2012 | Filed under Urology News | Permalink
Protox Therapeutics Changes Name to Sophiris Bio
SAN DIEGO , CA AND VANCOUVER , April 2, 2012 /CNW/ – Protox Therapeutics Inc. (TSX: PRX.TO – News) announced that it has changed its name to Sophiris Bio, Inc.
Read More..Posted on April 2, 2012 | Filed under Urology News | Permalink
Ampio Reaches Agreement with the TGA for the Submission Plan for Zertane in Australia
GREENWOOD VILLAGE, Colo., April 2, 2012 /PRNewswire/ –Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE – News) (“Ampio” or the “Company”), a company that discovers and develops new uses for previously approved drugs and new molecular entities (“NMEs”), announced today that it reached agreement with the Therapeutic Goods Administration (TGA), Canberra, Australia, on a plan of drug manufacture and quality control for Zertane and the overall plan for the preparation of Common Technical Documents for the draft registration submission expected to be filed in June 2012
Read More..Posted on April 2, 2012 | Filed under Urology News | Permalink
Targeted Drug Active in Refractory Urothelial Ca (CME/CE)
CHICAGO (MedPage Today) — Refractory urothelial cancer had meaningful responses in the majority of patients treated with the angiogenesis inhibitor pazopanib, results of a small clinical trial showed.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 1, 2012 | Filed under Urology News | Permalink
Clinical Notes: Fusion Drug Staves Off Cancer Progression
(MedPage Today) — Using trastuzumab to deliver a chemotherapy agent directly to cancer cells appeared to work in a phase III clinical trial. Also this week: failure for mesalamine in diverticulitis and delay for a new COPD drug.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 1, 2012 | Filed under Urology News | Permalink
PSA Drop Seen with New Prostate Ca Drug (CME/CE)
CHICAGO (MedPage Today) — Men with castration-resistant prostate cancer had biochemical responses to treatment with an investigational androgen receptor modulator, data from a preliminary clinical trial showed.Source:http://www.medpagetoday.com/rss/Urology.xml
Read More..Posted on April 1, 2012 | Filed under Urology News | Permalink
Aggressive Prostate Cancer Tumors Controlled By Botanical Formula
Editor’s Choice Academic Journal Main Category: Prostate / Prostate Cancer Also Included In: Urology / Nephrology Article Date: 29 Mar 2012 – 8:00 PDT email to a friend printer friendly opinions Current Article Ratings: 4.67 (6 votes) 5 (2 votes) The peer-reviewed pre-clinical in vivo study demonstrated that the prostate formula substantially suppresses tumor growth in aggressive, hormone-refractory (androgen-independent) human prostate cancer cells without any toxic side effects, even when administered at high doses. The formula is a combination of botanical extracts, phytonutrients, botanically enhanced medicinal mushrooms and antioxidants.
Read More..Posted on March 30, 2012 | Filed under Urology News | Permalink
Health Notes – BCBSNC announces challenge
Published: Thursday, March 29, 2012 at 10:40 a.m. Last Modified: Thursday, March 29, 2012 at 3:15 p.m. Southeastern N.C.
Read More..Posted on March 30, 2012 | Filed under Urology News | Permalink
Endo Announces Departure of American Medical Systems President
CHADDS FORD, Pa., March 29, 2012 /PRNewswire/ — Endo (Nasdaq: ENDP – News) announced today that American Medical Systems’ (AMS) Group President, Tony Bihl, will step down as head of the Endo devices operating company in July 2012.
Read More..Posted on March 30, 2012 | Filed under Urology News | Permalink